// STATE LEGISLATION TRACKER

Washington SB 5950: Making 2023-2025 fiscal biennium supplemental operating appropriations.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Washington
Bill: SB 5950
Filed: 2024-01-03
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Washington SB 5950 is a supplemental operating budget bill for the 2023-2025 fiscal biennium, not a peptide, prescribing, pharmacy, or telehealth policy bill. Based on the title and available bill information, it does not appear to change access to compounded peptides, off-label prescribing, clinician scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No apparent peptide-specific restrictions or expansions
No clear change to compounded peptide prescribing or dispensing
No apparent change to NP, naturopathic, or telehealth scope
No clear change to controlled-substance or PDMP rules

What to Watch For

Note This is a broad budget bill, so health funding details may exist without changing peptide rules.

Note Clinics should not treat this as a new prescribing or compounding authority change.

Note Any peptide impact would likely come from separate health, pharmacy, or professional-scope bills.

Where the Bill Stands

The bill passed the Legislature, was partially vetoed by the governor on March 29, 2024, and took effect as Chapter 376, 2024 Laws PV.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws